canosimibe

Small moleculeexperimental

Clinical trial activity

5 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
5
Phase 3
4
Phase 4
0

Earliest trial started Feb 1, 2007 (NCT00440154)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc([C@@H]2[C@@H](CC[C@H](O)c3ccc(F)cc3)C(=O)N2c2ccc(CNC(=O)CCCCCCCCCCC(=O)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)cc2)cc1
Mol. weight
809.97 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ave5530
  • ave5530

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00766688Phase 3Oct 1, 2008Sanofi
NCT00741715Phase 3Aug 1, 2008Radiant Research, Sanofi
NCT00718965Phase 3Jul 1, 2008Sanofi, Wake Forest University
NCT00729027Phase 3Jul 1, 2008Karolinska Institute, Sanofi
NCT00440154Phase 2Feb 1, 2007Sanofi
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SanofiFor profit5522007
Karolinska InstituteAcademic/Hospital1012008
Radiant ResearchAcademic/Hospital1012008
Wake Forest UniversityAcademic/Hospital1012008
4 organizations
Page 1 / 1